Eli Lilly has built a machine that keeps delivering. First-quarter revenue hit $19.8 billion. That marked a 56% jump from the year before. Mounjaro sales alone climbed 125% to $8.662 billion. Zepbound added another $4.16 billion, up 80%. And the company raised its full-year revenue outlook by $2 billion to a range of $82 billion to $85 billion.
Investors cheered the numbers. Yet one detail stood out more quietly. Outside the U.S., Lilly’s business grew even faster. International revenue reached $7.7 billion, an 81% increase. The Motley Fool reported that Morgan Stanley sees this as a signal many on Wall Street have missed. The bank estimates Lilly now commands slightly over 50% of the international GLP-1 market. In some places the share climbs higher.
India offers the clearest example. Novo Nordisk’s Wegovy lost patent protection there. Low-cost generics poured in. Logic suggested Lilly’s Mounjaro would suffer. Sales instead rose 10%. Morgan Stanley called it a big story investors are missing. A halo effect took hold. Greater awareness of the category lifted demand for the more effective option. Mounjaro simply worked better on weight loss than Wegovy.
The pattern repeats elsewhere. Morgan Stanley’s analysis, referenced in recent coverage, puts Lilly’s international incretin share at roughly 53%. It reaches about 60% in Brazil and Korea. In Europe, where prescription data flows more freely, the figure has stayed above 55% since obesity launches began in early 2024. Four straight quarters of beating overseas estimates have followed. Mounjaro now sells in more than 55 countries.
But the competition refuses to stand still. Novo Nordisk reached the market first with a GLP-1 pill. Patients prefer tablets to injections. Eli Lilly answered with its own oral version, Foundayo, also known as orforglipron. Regulators approved it for adults with obesity. Yet Lilly’s pill appears less potent than its injectable twins. The gap gives Novo Nordisk a temporary opening on the convenience front.
Lilly isn’t waiting for that edge to close. The company has a next-generation candidate, retatrutide, moving through trials. Early phase 3 data showed patients on the highest dose losing about 30% of body weight over two years. The Wall Street Journal noted the results raise the bar in the category. Retatrutide also met key secondary endpoints. Success here could blunt competition from both Novo and any future rivals.
Supply remains the persistent constraint. Demand for these drugs far outruns current capacity. Lilly has responded with aggressive spending. The company committed at least $27 billion to four new U.S. manufacturing sites. An additional $4.5 billion went toward its massive Indiana complex. Total domestic investment since 2020 now exceeds $50 billion. Executives say the builds target not only current GLP-1 products but also genetic medicines and the broader pipeline.
David A. Ricks, Lilly’s chair and CEO, struck an upbeat tone in the April 30 earnings release. “2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion,” he said. The company also flagged positive late-stage data for several assets, including retatrutide in type 2 diabetes and combinations involving Zepbound.
Valuation tells a more complicated tale. Shares traded near $1,067 after the latest move, with the stock showing a price-to-earnings ratio around 38 times. That sits well below the five-year average of 56 times. Market capitalization hovers near $1 trillion. Gross margin sits at 82%. The dividend yield is modest at 0.61%. Aggressive growth investors see room to run if international momentum holds. Value buyers still hesitate.
Recent analyst commentary reinforces the optimism. Truist kept a buy rating after the retatrutide readout and cited a strengthened long-term case. Citi’s Meacham told viewers that both Eli Lilly and Novo Nordisk can expand their positions in the GLP-1 space this year as access broadens. Goldman Sachs listed Lilly among stocks less tied to the artificial-intelligence trade, suggesting it as a diversifier.
Yet risks linger. Pricing pressure has already trimmed realized prices on Mounjaro and Zepbound. Regulatory scrutiny of the entire obesity-drug class could intensify. Manufacturing scale-up carries execution risk even with billions committed. And any slowdown in the international surge would test whether the current multiple holds.
Lilly’s bet looks straightforward on paper. Keep capacity coming online. Push the superior efficacy of its injectable portfolio while the oral options mature. Expand into new geographies where the data show resilience. Morgan Stanley’s read on India and the broader ex-U.S. market suggests that strategy is gaining traction faster than many models assume. The next few quarters will test whether that confidence proves justified.
So far the numbers back the thesis. Sales growth continues to outpace expectations. Pipeline catalysts sit on the horizon. Manufacturing investments address the most obvious bottleneck. The stock has run hard in recent years. But if international share keeps climbing and the next-generation drugs deliver, the case for further upside remains intact. Wall Street may still be catching up to what Lilly is building outside its home market.
WebProNews is an iEntry Publication